Oncotelic Therapeutics, Inc. (OTCMKTS:OTLC) Short Interest Update

Oncotelic Therapeutics, Inc. (OTCMKTS:OTLC) was the recipient of a significant increase in short interest in October. As of October 15th, there was short interest totaling 122,300 shares, an increase of 122,200.0% from the September 30th total of 100 shares. Currently, 0.0% of the shares of the stock are sold short. Based on an average daily trading volume, of 1,155,500 shares, the short-interest ratio is currently 0.1 days. Based on an average daily trading volume, of 1,155,500 shares, the short-interest ratio is currently 0.1 days. Currently, 0.0% of the shares of the stock are sold short.

Oncotelic Therapeutics Price Performance

Shares of OTCMKTS:OTLC opened at $0.10 on Tuesday. The business’s 50 day simple moving average is $0.07 and its 200-day simple moving average is $0.06. The firm has a market capitalization of $41.80 million, a price-to-earnings ratio of -9.52 and a beta of -0.69. Oncotelic Therapeutics has a 12 month low of $0.02 and a 12 month high of $0.11.

Oncotelic Therapeutics Company Profile

Oncotelic Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in developing drugs for the treatment of orphan oncology indications. The company's lead product candidate is OT-101, an antisense against TGF-ß2, which is in phase 3 clinical trials for pancreatic cancer and glioblastoma, as well as develops OT-101 for the treatment of various viruses, including severe acute respiratory syndrome and coronavirus.